PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

NCT02487277 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Adenocarcinoma

Interventions

DRUG: PEGPH20
DRUG: Gemcitabine
DRUG: Nab-paclitaxel

Sponsor

Andrew Ko